Virtual Library

Start Your Search

Konstantinos Syrigos



Author of

  • +

    EP1.01 - Advanced NSCLC (ID 150)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.01-69 - Safety and Efficacy of Percutaneous Computed Tomography-Guided Thermal Ablation of Non-Small Cell Lung Cancer Metastases (Now Available) (ID 1147)

      08:00 - 18:00  |  Author(s): Konstantinos Syrigos

      • Abstract
      • Slides

      Background

      Percutaneous computed tomography-guided (CT-guided) thermal ablation is a minimally invasive method for the treatment of adrenal metastases, painful bone metastases and liver metastases originating from non-small cell lung cancer (NSCLC). We aimed to further evaluate the safety and efficacy of CT-guided radiofrequency ablation (RFA) and microwave ablation (MWA) in the management of metastases in a real-life cohort of NSCLC patients.

      Method

      The medical records of 142 patients with metastatic NSCLC (71, 32 and 40 patients with adrenal metastases, painful bone metastases and liver metastases, respectively) treated with CT-guided RFA or MWA were retrospectively studied. The efficacy of thermal ablation was evaluated by post-ablation imaging. For painful bone metastases, palliation was assessed by the Brief Pain Inventory (BPI) score.

      Result

      Technical success of CT-guided thermal ablation was 100%. No major complications occurred. Among patients with adrenal metastases treated with RFA or MWA, local recurrence was observed in 17.1% and 19.4% of cases at 1-year follow up, respectively. In patients with painful bone metastases, significant pain relief was noted after thermal ablation (p<0,001). Local recurrence was observed in 3.3% of cases with liver metastases at 1-year follow-up.

      Conclusion

      CT-guided RF and MW ablation is a safe and effective local treatment for the management of adrenal, bone and liver metastases from NSCLC. For painful bone metastases RF ablation provides significant pain relief.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    EP1.11 - Screening and Early Detection (ID 201)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Screening and Early Detection
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.11-03 - Diagnostic Evaluation of Patients with Solitary Pulmonary Nodules in a Tertiary Referral Center (Now Available) (ID 1145)

      08:00 - 18:00  |  Author(s): Konstantinos Syrigos

      • Abstract
      • Slides

      Background

      Management of patients with Solitary Pulmonary Nodules (SPN) is primarily targeted at achieving an early diagnosis and treatment of all malignant nodules. We herein aimed to assess the adherence of pulmonologists to current clinical practice guidelines for SPN evaluation in a tertiary referral center for thoracic diseases.

      Method

      The medical records of 64 patients with SPN, diagnosed and treated at Sotiria Hospital for Chest Diseases from January 2017 to September 2018 were retrospectively reviewed. Following analysis of the clinical features and imaging characteristics of all cases, the probability of malignancy was evaluated, and the management approach followed by pulmonologists was compared to the approach suggested by issued guidelines.

      Result

      We observed a tendency by pulmonologists to monitor all SPN irrespective of size, density and likelihood of malignancy and reassess them at an earlier time than recommended by guidelines. Use of PET/CT in solid nodules > 8 mm of very low (50%) and high (80%) probability of malignancy was also observed, despite lack of a clear indication of PET/CT in the above patients’ groups. Conventional bronchoscopy was performed in 81% of patients with a SPN of > 8 mm with intermediate and high probability of malignancy, even though this is not typically recommended. A low-dose protocol was applied in the majority of SPN cases monitored by computed tomography, in accordance with guidelines. Malignancy was diagnosed in 42/64 patients.

      Conclusion

      Pulmonologists in real-world practice may adopt a more "aggressive" management approach towards patients with SPN, so as to exclude the possibility of an underlying malignancy.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.01 - Advanced NSCLC (ID 159)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.01-54 - Real-World PD-L1 Testing Patterns for Patients with Advanced Non-Small Cell Lung Cancer in Greece (ID 2138)

      10:15 - 18:15  |  Presenting Author(s): Konstantinos Syrigos

      • Abstract
      • Slides

      Background

      Programmed Cell Death Protein-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) inhibitors are important immunotherapy targets for non-small cell lung cancer (NSCLC). This study sought to describe PD-L1 testing for patients with NSCLC in Greece.

      Method

      This non-interventional study is based on Sotiria Lung Cancer Registry in Greece recording patients with histologically or cytologically confirmed stage IIIB/IV NSCLC diagnosis, who initiated systemic treatment between August, 15th 2016 and August, 14th 2018.

      Result

      A total of 472 patients were included in the registry. Demographic and first-line treatment information are presented in Table 1, along with the respective comparison between patients tested and not tested for PD-L1. Patients with ECOG PS 0-1 are more likely to be tested for PD-L1 status. Among patients tested for PD-L1, Dako 22C3 was the most commonly used testing assay (87.8%).

      The number of patients tested for PD-L1 increased between the two consecutive time periods (from August, 15th 2016 to August, 14th 2018; Table 2).

      table 1.jpg

      table 2.jpg

      Conclusion

      The percentage of newly diagnosed patients with advanced NSCLC in Greece tested for PD-L1 status doubled in a year (August, 15th 2016 – August, 14th 2018). Among those tested, 67% were tested prior to first-line treatment initiation and 26% of those tested had PD-L1 TPS ≥50%.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.